ILV3 Gene Detection for Candida and Aspergillus

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for detecting fungal infections, particularly those caused by Candida and Aspergillus species, are slow and often result in unnecessary antibiotic administration due to lack of specificity and cross-reactivity with human DNA, leading to antibiotic resistance and delayed diagnosis.

Innovation Solution

The use of the ILV3 gene, which encodes dihydroxyacid dehydratase, as a novel target for molecular detection, employing specific primers and probes that do not cross-react with human DNA, allowing for rapid and specific identification of Candida and Aspergillus species using PCR and melt curve analysis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If molecular tests using known targets (ribosomal DNA, ILV5, or other candidate genes) are employed, then detection sensitivity may be improved, but false positive results occur due to cross-reactivity with human DNA

Engineering Contradiction:
Improvedetection specificityVSAvoidfalse positive rate
Core Design Contradiction:
Measurement precisionVSReliability

Solution Approach 1:

The patent extracts and isolates the ILV3 gene as a specific detection target that is unique to fungi and yeasts, separating it from human DNA sequences. By designing primers and probes that specifically bind only to the ILV3 gene, the method eliminates cross-reactivity with human genetic material while maintaining high detection sensitivity for fungal and yeast infections.

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent applies local quality by designing detection reagents with sequence specificity tailored to the ILV3 gene's unique regions. The primers and probes are engineered to recognize specific local sequences within the ILV3 gene that differ from human DNA, ensuring that detection occurs only at the intended target site without off-target binding to human genomic regions.

Inventive Principle:
Principle #3Local quality

2Reliability

If culture-based identification methods are used, then reliability of diagnosis is maintained, but detection time is excessively long (around 5 days)

Engineering Contradiction:
Improvediagnostic accuracyVSAvoiddetection time
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The patent performs preliminary action by using molecular amplification methods (PCR) to rapidly detect and identify fungal and yeast DNA before clinical symptoms fully develop or before culture results are available. This allows for early diagnosis and immediate initiation of appropriate antifungal therapy, reducing the 5-day delay inherent in culture-based methods while maintaining diagnostic reliability through specific molecular targeting.

Inventive Principle:
Principle #10Preliminary action

3Reliability

If broad-spectrum antibiotics are administered empirically, then coverage of potential infections is maximized, but antibiotic resistance develops due to unnecessary use

Engineering Contradiction:
Improveinfection coverageVSAvoidantibiotic resistance
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent implements feedback by providing rapid molecular diagnostic results that inform clinical decision-making. The ILV3 gene detection method delivers same-day or next-day results that feedback to clinicians, allowing them to adjust antibiotic prescribing based on actual fungal or yeast infection status. This feedback loop reduces unnecessary broad-spectrum antibiotic use by enabling targeted antifungal therapy when fungal infections are confirmed, thereby reducing the development of antibiotic resistance.

Inventive Principle:
Principle #23Feedback

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables rapid, specific, and sensitive detection of fungal infections, reducing antibiotic misuse and improving diagnostic speed, thereby addressing antibiotic resistance and patient safety.

Implementation Method 1

US7291724 and US7169555 describe oligonucleotides binding to ribosomal DNA that can be used in PCR reactions

Methodology Applied
Scientific EffectHybridization:

Implementation Method 2

Further amplification based methods for the detection of fungus/yeast are known

Methodology Applied
Scientific EffectPCR amplification:

Implementation Method 3

Melt curve analysis may be employed as a method of determining which species is present in the sample

Methodology Applied
Scientific EffectMelt curve analysis:

Data Source

PatentEP3610044B1Detection and delineation of microorganisms using the ILV3 gene
Publication Date: 2022.01.05 MOMENTUM BIOSCIENCE LTD
  • EP3610044B1 patent drawingFigure 1
  • EP3610044B1 patent drawingFigure 2
  • EP3610044B1 patent drawingFigure 3A

AI summary

Methods for detecting a fungal/yeast infection in a sample, comprising: performing a nucleic acid amplification reaction to amplify the ILV3 gene of fungi/yeast; and detecting the amplification product to determine whether the sample contains a fungal/yeast infection. Corresponding primers, probes and kits are also provided.